Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 3881-3887

  Cortes, Jose R ^a   Perez G, Moises ^a   Rivas, Maria D ^a   Zamorano, Jose ^a  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; BUTEIN; ESCULETIN; FISETIN; FLAVONOL; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; JANUS KINASE 1; JANUS KINASE 3; KAEMPFEROL; LUTEOLIN; MORIN; MYRICETIN; PHENETHYLSALICYLIC ACID; PROTEIN TYROSINE KINASE; ROSMARINIC ACID; SALICYLIC ACID DERIVATIVE; STAT6 PROTEIN; UNCLASSIFIED DRUG; JAK1 PROTEIN, HUMAN; JAK3 PROTEIN, HUMAN; KAEMPFEROL DERIVATIVE; PROTEIN KINASE INHIBITOR; STAT6 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL STRAIN HL 60; CELL STRAIN U937; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HL-60 CELLS; HUMANS; INTERLEUKIN-4; JANUS KINASE 1; JANUS KINASE 3; KAEMPFEROLS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; STAT6 TRANSCRIPTION FACTOR; U937 CELLS;

EID: 35748973566     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.3881     Document Type: Article

References (44)

1. Paul, W. E. 1991. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77: 1859-1870.
2. Zamorano, J., H. Y. Wang, L. M. Wang, J. H. Pierce, and A. D. Keegan. 1996. IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. J. Immunol. 157: 4926-4934.
3. Lutz, M. B., M. Schnare, M. Menges, S. Rossner, M. Rollinghoff, G. Schuler, and A. Gessner. 2002. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J. Immunol. 169: 3574-3580.
4. Yanagida, M., H. Fukamachi, K. Ohgami, T. Kuwaki, H. Ishii, H. Uzumaki, K. Amano, T. Tokiwa, H. Mitsui, and H. Saito. 1995. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86: 3705-3714.
5. Urban, J. F., N. Noben-Trauth, D. D. Donaldson, K. B. Madden, S. C. Morris, M. Collins, and F. D. Finkelman. 1998. IL-13, IL-4Ra, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite N. brasiliensis. Immunity 8: 255-264.
6. Finnegan, A., M. J. Grusby, C. D. Kaplan, S. K. O'Neill, H. Eibel, T. Koreny, M. Czipri, K. Mikecz, and J. Zhang. 2002. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J. Immunol. 169: 3345-3352.
7. Tomkinson, A., C. Duez, G. Cieslewicz, J. C. Pratt, A. Joetham, M. C. Shanafelt, R. Gundel, and E. W. Gelfand. 2001. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J. Immunol. 166: 5792-5800.
8. Prokopchuk, O., Y. Liu, D. Henne-Bruns, and M. Kornmann. 2005. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Brit. J. Cancer 92: 921-928.
9. Nelms, K., A. D. Keegan, J. Zamorano, J. J. Ryan, and W. E. Paul. 1999. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17: 701-738.
10. Russell, S. M., A. D. Keegan, N. Harada, Y. Nakamura, M. Noguchi, P. Leland, M. C. Friedmann, A. Miyajima, R. K. Puri, W. E. Paul, and W. J. Leonard. 1993. Interleukin-2 receptor γ chain: a functional component of the interleukin-4 receptor. Science 262: 1880-1883.
11. Miloux, B., P. Laurent, O. Bonnin, J. Lupker, D. Caput, N. Vita, and P. Ferrara. 1997. Cloning of the human IL-13Ral chain and reconstitution with the IL4Ra of a functional IL-4/1L-13 receptor complex. FEBS Lett. 401: 163-166.
12. Hershey, G. K. 2003. IL-13 receptors and signalling pathways: an evolving web. J. Allergy Clin. Immunol. 111: 677-690.
13. Perez-G, M., M. Melo, A. D. Keegan, and J. Zamorano. 2002. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J. Immunol. 168: 1428-1434.
14. Takeda, K., T. Tanaka, W. Shi, M. Matsumoto, M. Minami, S. Kashiwamura, K. Nakanishi, N. Yoshida, T. Kishimoto, and S. Akira. 1996. Essential role of Stat6 in IL-4 signalling. Nature 380: 627-630.
15. Chitnis, T., N. Najafian, C. Benou, A. D. Salama, M. J. Grusby, M. H. Sayegh, and S. J. Khoury. 2001. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 108: 739-747.
16. Akimoto, T., F. Numata, M. Tamura, Y. Takata, N. Higashida, T. Takashi, K. Takeda, and S. Akira. 1998. Abrogation of bronquial eosinophilic inflamation and airways hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J. Exp. Med. 187: 1537-1542.
17. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1: 515-520.
18. Middleton, E. Jr., C. Kandaswami, and T. C. Theoharides. 2000. The effects of plant flavonoides on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52: 673-751.
19. Havsteen, B. H. 2002. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96: 67-202.
20. Knekt, P., J. Kumpulainen, R. Jarvinen, H. Rissanen, M. Heliovaara, A. Reunanen, T. Hakulinen, and A. Aromaa. 2002. Flavonoid intake and risk of chronic disease. Am. J. Clin. Nutr. 76: 560-568.
21. Shaheen, S. O., J. A. Sterne, R. L. Thompson, C. E. Songhurst, B. M. Margetts, and P. G. Burney. 2001. Dietary antioxidants and asthma in adults: population-based case-control study. Am. J. Respir. Crit. Care Med. 164: 1823-1828.
22. Lu, J., L. V. Papp, J. Fang, S. Rodriguez-Nieto, B. Zhivotovsky, and A. Holmgren. 2006. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res. 66: 4410-4418.
23. Chen, C. C., M. P. Chow, W. C. Huang, Y. C. Lin, and Y. J. Chang. 2004. Flavonoids inhibit tumor necrosis factor-α-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-κB: structure-activity relationships. Mol. Pharmacol. 66: 683-693.
24. Lolito, S. B., and B. Frei. 2006. Dietary flavonoids attenuate tumor necrosis factor α-induced adhesion molecule expression in human aortic endothelial cells: structure-function relationships and activity after first pass metabolism. J. Biol. Chem. 281: 37102-37110.
25. Birrell, M. A., K. McCluskie, S. Wong, L. E. Donnelly, P. J. Barnes, and M. G. Belvisi. 2005. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-κ-independent mechanism. FASEB J. 19: 840-841.
26. Wang, H. Y., W. E. Paul, and A. Keegan. 1996. IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor a chain. Immunity 4: 113-121.
27. Soriano, P., C. Montgomery, R. Geske, and A. Bradley. 1991. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64: 693-702.
28. Muller, M., J. Briscoe, C. Laxton, D. Guschin, A. Ziemiecki, O. Silvennoinen, A. G. Harpur, G. Barbieri, B. A. Witthuhn, C. Schindler, et al. 1993. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction. Nature 366: 129-135.
29. Denizot, F., and R. Lang. 1986. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 22: 271-277.
30. Chen, X. H., B. K. Patel, L. M. Wang, M. Frankel, N. Ellmore, R. A. Flavell, W. J. LaRochelle, and J. H. Pierce. 1997. Jak1 expression is required for mediating interleukin-4-induced tyrosine phosphorylation of insulin receptor substrate and Stat6 signalling molecules. J. Biol. Chem. 272: 6556-6560.
31. Daniel, C., A. Salvekar, and U. Schindler. 2000. A gain-of-function mutation in STAT6. J. Biol. Chem. 275: 14255-14259.
32. Miyazaki, T., A. Kawahara. H. Fujii, Y. Nakagawa, Y. Minami, Z. J. Liu, I. Oishi, O. Silvennoinen, B. A. Witthuhn, J. N. Ihle, and T. Taniguchi. 1994. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266: 1045-1047.
33. Reddy, E. P., A. Korapati, P. Chaturvedi, and S. Rane. 2000. IL-3 signalling and the role of Src kinases, JAKs and STATs: a cover liaison unveiled. Oncogene 19: 2532-2547.
34. Zamorano, J., H. Y. Wang, R. X. Wang, Y. Shi, G. D. Longmore, and A.D. Keegan. 1998. Regulation of cell growth by IL-2: role of STAT5 in protection from apoptosis but not in cell cycle progression. J. Immunol. 160: 3502-3512.
35. Pesu, M., F. Candotti, M. Husa, S. R. Hofmann, L. D. Notarangelo, and J. J. O'Shea. 2005. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol. Rev. 203: 127-142.
36. Changelian, P. S., M. E. Flanagan, D. J. Ball, C. R. Kent, K. S. Magnuson, W. H. Martin, B. J. Rizzuti, P. S. Sawyer, B. D. Perry, W. H. Brissette, et al. 2003. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878.
37. Nikolic, B., S. Lee, R. T. Bronson, M. J. Grusby, and M. Sykes. 2000. Th1 and Th2 mediate acute graft-versus-host-disease, each with distinct end-organ targets. J. Clin. Invest. 105: 1289-1298.
38. Oku, H., and K. Ishiguro. 2001. Antipruritic and antidermatitic effect of extract and compounds of Impatiens balsamina L. in atopic dermatitis model NC mice. Phytother. Res. 15: 506-510.
39. Ishiguro, K., Y. Ohira, and H. Oku. 2002. Preventive effects of Impatiens balsamina on the hen egg-white lysozyme (HEL)-induced decrease in blood flow. Biol. Pharm. Bull. 25: 505-508.
40. Yamaoka, K., B. Min, Y. J. Zhou, W. E. Paul, and J. J. O'Shea. 2005. Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood 106: 3227-3233.
41. Nakamura, Y., C. Chang, T. Mori, K. Sato, K. Ohtsuki, B. L. Upham, and J. E. Trosko. 2005. Augmentation of differentiation and gap function by kaempferol in partially differentiated colon cancer cells. Carcinogenesis 26: 665-671.
42. Kirken, R. A., R. A. Erwin, L. Wang, Y. Wang, H. Rui, and W. L. Farrar. 2000. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukaemia virus type 1-transformed human T cells. J. Immunol. 165: 5097-5104.
43. Sudbeck, E. A., X. P. Liu, R. K. Narla, S. Mahajan, S. Ghosh, C. Mao, and F. M. Uckun. 1999. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5: 1569-1582.
44. Brown, G., R. A. M. Bamford, J. Bowyer, D. S. James, N. Rankine, E. Tang, V. Torr, and E. J. Culbert. 2000. Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg. Med. Chem. Lett. 10: 575-579.